Author

Shu‐Ching Chang

ORCID 0000-0002-6534-0124Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Alexa K. DowdelliD· 1 shared Ann VitaiD· 1 shared Bela Bapat· 1 shared Brian PieningiD· 1 shared Brock Schroeder· 1 shared Carlo Bruno BifulcoiD· 1 shared Cliff WongiD· 1 shared Douglas Allen HanesiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Alexa K. DowdellORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system

Alexa K. Dowdell, Ryan Meng, Ann Vita, Bela Bapat, Douglas Allen Hanes, Shu‐Ching Chang, Lauren Harold, Mark Schmidt, Cliff Wong, Hoifung Poon, Brock Schroeder, Roshanthi K. Weerasinghe, Rom S. Leidner, Walter John Urba, Carlo Bruno Bifulco, Brian Piening

This study shows that precision therapies have become more common than traditional chemotherapy in advanced cancer patients after implementing comprehensive genomic profiling.

JCO Oncology Practice · Nov 1, 2024Peer-reviewedGenetic & Genomic Medicine